Literature DB >> 20162546

Is the JAK2(V617F) mutation detectable in healthy volunteers?

Christophe Martinaud, Patrick Brisou, Marie-Joelle Mozziconacci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20162546     DOI： 10.1002/ajh.21627

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  10 in total

1.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

Review 2.  Ethical considerations in genomic testing for hematologic disorders.

Authors:  Jonathan M Marron; Steven Joffe
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

3.  Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

Authors:  Eric Lippert; Olivier Mansier; Marina Migeon; Barbara Denys; Asa Nilsson; Carolina Rosmond; Laurence Lodé; Valérie Ugo; Axelle Lascaux; Beatriz Bellosillo; Joaquin Martinez-Lopez; Dina Naguib; Nathalie Gachard; Nicolas Maroc; Sylvie Hermouet
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

4.  The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.

Authors:  Camilla Nielsen; Henrik S Birgens; Børge G Nordestgaard; Lasse Kjaer; Stig E Bojesen
Journal:  Haematologica       Date:  2010-12-15       Impact factor: 9.941

5.  Frequency of Zygosity in Jak-2 Positive Patients with Polycythemia Vera-Pakistan's Perspective.

Authors:  Syed Zubair Shah; Naila Raza; Muhammad Israr Nasir; Syed Mustanir Hussain Zaidi
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

6.  Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

Authors:  E Kouroupi; J-J Kiladjian; C Dosquet; M-L Menot; N Bonnin; L Ades; W Vainchenker; C Chomienne; B Cassinat
Journal:  Blood Cancer J       Date:  2012-05-04       Impact factor: 11.037

7.  Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg.

Authors:  Mandy N Lauw; Erik W N Bus; Alexander F Y van Wulfften Palthe; Michiel Coppens; Christa H Homburg; Saskia Middeldorp; C Ellen van der Schoot; Harry R Koene; Bart J Biemond
Journal:  Ann Hematol       Date:  2011-04-12       Impact factor: 3.673

8.  Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.

Authors:  Shuyu D Li; Meng Ma; Hui Li; Aneta Waluszko; Tatyana Sidorenko; Eric E Schadt; David Y Zhang; Rong Chen; Fei Ye
Journal:  Genome Med       Date:  2017-10-30       Impact factor: 11.117

9.  The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Authors:  Margherita Perricone; Nicola Polverelli; Giovanni Martinelli; Lucia Catani; Emanuela Ottaviani; Elisa Zuffa; Eugenia Franchini; Arbana Dizdari; Dorian Forte; Elena Sabattini; Michele Cavo; Nicola Vianelli; Francesca Palandri
Journal:  Oncotarget       Date:  2017-06-06

10.  Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Authors:  Margherita Perricone; Francesca Palandri; Emanuela Ottaviani; Mario Angelini; Laura Bagli; Enrica Bellesia; Meris Donati; Donato Gemmati; Patrizia Zucchini; Stefania Mancini; Valentina Marchica; Serena Trubini; Giovanna De Matteis; Silvia Di Zacomo; Mosè Favarato; Annamaria Fioroni; Caterina Bolzonella; Giorgia Maccari; Filippo Navaglia; Daniela Gatti; Luisa Toffolatti; Linda Orlandi; Vèronique Laloux; Marco Manfrini; Piero Galieni; Barbara Giannini; Alessia Tieghi; Sara Barulli; Maria Luisa Serino; Monica Maccaferri; Anna Rita Scortechini; Nicola Giuliani; Daniele Vallisa; Massimiliano Bonifacio; Patrizia Accorsi; Cristina Salbe; Vinicio Fazio; Milena Gusella; Eleonora Toffoletti; Marzia Salvucci; Mirija Svaldi; Filippo Gherlinzoni; Francesca Cassavia; Francesco Orsini; Giovanni Martinelli
Journal:  Oncotarget       Date:  2017-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.